JP 1302

Drug Profile

JP 1302

Alternative Names: JP-1302

Latest Information Update: 16 Feb 2009

Price : $50

At a glance

  • Originator Juvantia Pharma
  • Class Antiparkinsonians; Imidazoles; Indans; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Major depressive disorder

Most Recent Events

  • 01 Feb 2001 Preclinical development for Depression in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top